Endometriosis Activity Independent of Menstruation: Hormonal Drivers and Clinical Implications

Endometriosis (endometrial-like tissue outside uterus) is **estrogen-dependent** but **not menstruation-dependent**. Lesions can grow, bleed, and cause inflammation even during amenorrhea.

Hormonal Drivers

  • Estrogen: Ovarian (cyclic), peripheral (adipose aromatase), **lesion-derived** (aromatase, steroidogenic acute regulatory protein – StAR). Endometriotic tissue produces its own estrogen → autocrine/paracrine loop.
  • Progesterone resistance: ↓ PR-B isoform, ↑ inflammatory response to progesterone. Limits efficacy of progestin therapy.
  • Inflammatory cytokines: TNF-α, IL-1β, IL-6, IL-8, RANTES → angiogenesis, nerve growth, pain sensitization.
  • Prostaglandins (PGE2, PGF2α): Produced by lesions → pain, uterine contractions, inflammation.

Activity Without Menses

  • Hormonal suppression (GnRH agonists, combined OCs, progestins, danazol): ↓ ovarian estrogen but **lesion estrogen persists** → residual activity.
  • Pregnancy: High progesterone + placental hormones → decidualization, often quiescence. But not universal; some worsen.
  • Menopause: Ovarian estrogen ceases. Peripheral/lesion estrogen may sustain symptoms. HRT can reactivate.
  • Aromatase inhibitors (letrozole) + GnRH analog: Target local estrogen – used in severe refractory cases (off-label, bone loss risk).

Clinical Implications

  • Pain ≠ menstrual cycle phase. Chronic pelvic pain, dyspareunia, bowel/bladder symptoms may persist continuously.
  • Suppression ≠ cure. Lesions may remain viable; recurrence common after stopping therapy.
  • Surgery (excision > ablation) removes lesions but not microscopic disease or predisposition.
  • Multimodal: medical suppression + surgery + pelvic PT + pain neuroscience + dietary/lifestyle (anti-inflammatory).

Emerging Targets

  • Selective progesterone receptor modulators (SPRMs), IL-33/ST2 axis, nerve growth factor (NGF) inhibitors, cannabis-based medicines.

Endometriosis is a chronic systemic inflammatory disease, not just "period pain." Management requires addressing estrogen independence and central sensitization.

Infertility - Related Articles